Advertisement
Screener

NASDAQ:AVIR | Increase (Decrease) in Contract with Customer, Liability | Atea Pharmaceuticals, Inc.

0.4 / 5 stars · 10/120 Roast Me

Atea Pharmaceuticals, Inc. Increase (Decrease) in Contract with Customer, Liability

Discontinued › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2023-02-28

  • Atea Pharmaceuticals, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2021-12-31 was -$192.18M.
  • Atea Pharmaceuticals, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2021-09-30 was -$32.81M.
  • Atea Pharmaceuticals, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2021-06-30 was -$10.39M.
  • Atea Pharmaceuticals, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2021-03-31 was -$65.98M.
  • Atea Pharmaceuticals, Inc. increase (decrease) in contract with customer, liability for fiscal 2021 was -$301.37M, a 200.00% decline from fiscal 2020.
  • Atea Pharmaceuticals, Inc. increase (decrease) in contract with customer, liability for fiscal 2020 was $301.37M.
Period endIncrease (Decrease) in Contract with Customer, Liability 3 monthIncrease (Decrease) in Contract with Customer, Liability 6 monthIncrease (Decrease) in Contract with Customer, Liability 9 monthIncrease (Decrease) in Contract with Customer, Liability 12 month
2021-12-31-$192.18M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28
-$224.99M
derived: sum of 2 quarters · filed 2023-02-28
-$235.38M
derived: sum of 3 quarters · filed 2023-02-28
-$301.37M
10-K · filed 2023-02-28
2021-09-30-$32.81M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07
-$43.20M
derived: sum of 2 quarters · filed 2022-11-07
-$109.19M
10-Q · filed 2022-11-07
2021-06-30-$10.39M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08
-$76.38M
10-Q · filed 2022-08-08
2021-03-31-$65.98M
10-Q · filed 2022-05-10
2020-12-31$301.37M
10-K · filed 2023-02-28